Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sarepta Therapeutics
(NQ:
SRPT
)
135.78
-1.47 (-1.07%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Why Are Stocks Down Today?
October 31, 2023
Stocks are down today and investors wondering why have come to the right place as we have an answer to that question!
Via
InvestorPlace
BB Stock Alert: What to Know as BlackBerry Announces CEO Departure
October 31, 2023
BlackBerry stock is falling on Tuesday as investors in BB react to news of CEO John Chen departing from the company this week.
Via
InvestorPlace
US Stocks Fall; Pfizer Swings To Q3 Loss
October 31, 2023
U.S. stocks traded lower this morning, following the release of economic reports. Following the market opening Tuesday, the Dow traded down 0.25% to 32,845.12 while the NASDAQ fell 0.50% to 12,726.17....
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is Sarepta Therapeutics (SRPT) Stock Down 47% Today?
October 31, 2023
Sarepta Therapeutics stock is dropping with heavy trading as SRPT investors take in the lackluster results from a Phase 3 clinical trial.
Via
InvestorPlace
Why Pinterest Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
October 31, 2023
Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 38.8% to $0.1250 in pre-market trading. LumiraDX shares fell 25% on Monday after the company announced the receipt of the Nasdaq delisting...
Via
Benzinga
5 Analysts Have This to Say About Sarepta Therapeutics
September 26, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 31, 2023
Via
Benzinga
Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny - Stock Tanks
October 31, 2023
Sarepta Therapeutics Inc (NASDAQ: SRPT) released topline results from EMBARK (Study SRP-9001-301) Phase 3 study of Elevidys (delandistrogene moxeparvovec-rokl) in ambulatory boys (those who can walk)...
Via
Benzinga
Exposures
Product Safety
Pinterest To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Tuesday
October 31, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
EMBARKNG On A New Label? New Sarepta DMD Data Leads To Old Debates
October 30, 2023
Sarepta released their Phase III EMBARK data that is actually consistent with my previous analysis that the drug likely works in younger patients but not older.
Via
Talk Markets
Sarepta Therapeutics Stock Halted After Unveiling Mixed Results For Its First Gene Therapy
October 30, 2023
The drug didn't meet its primary goal in the pivotal study, but it met secondary measures.
Via
Investor's Business Daily
Sarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy
October 30, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
October 27, 2023
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
October 25, 2023
Via
Benzinga
Sarepta Therapeutics to Announce Third Quarter 2023 Financial Results
October 25, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
October 24, 2023
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
October 19, 2023
Via
Benzinga
3 Gene Editing Stocks to Generate Super-Charged Gains
October 18, 2023
As things progress, such techniques may be able to knock out every disease known, creating massive opportunity for gene-editing stocks.
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
October 10, 2023
Via
Benzinga
Sarepta Therapeutics Stock Showing Rising Relative Strength
October 09, 2023
Sarepta Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating
Via
Investor's Business Daily
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 29, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
September 29, 2023
Via
Benzinga
Are Gene Therapy Stocks The Market's Next Big Winners?
September 25, 2023
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
10 Health Care Stocks Whale Activity In Today's Session
September 18, 2023
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
September 15, 2023
Via
Benzinga
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
September 15, 2023
Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions.
Via
Investor's Business Daily
Exposures
Product Safety
10 Health Care Stocks With Whale Alerts In Today's Session
September 14, 2023
Via
Benzinga
2 Top Growth Stocks to Buy With $500
September 14, 2023
No need to break the bank to invest in stocks.
Via
The Motley Fool
Insiders Are Buying These 2 Stocks
September 08, 2023
Insider buying in both Loews (NYSE: L) and Sarepta (NASDAQ: SRPT) suggests a positive outlook for these stocks, potentially influencing investor sentiment.
Via
MarketBeat
Sarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year
September 07, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.